Last reviewed · How we verify
Amphothalide (AMPHOTALIDE)
Amphothalide (generic name: AMPHOTALIDE) is a drug. It is currently in Phase 2 development.
Amphothalide works by binding to a specific target, although the identity of this target is currently unknown.
Amphothalide is a small molecule modality developed by an unknown entity, currently owned by an unknown entity. Its target and drug class are unknown, and it has not been approved by the FDA for any indications. The commercial status of Amphothalide is unclear, and it is not known whether it is patented or available as a generic. Further information on its pharmacokinetic properties, such as half-life and bioavailability, is also unavailable. As a result, key safety considerations and potential side effects are unknown.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AMPHOTALIDE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Think of Amphothalide like a key that fits into a lock. The lock is a specific part of a cell, and the key is the Amphothalide molecule. When the key fits into the lock, it can change the way the cell works, which can help to treat a disease. However, the exact details of how Amphothalide works are still unclear.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amphothalide CI brief — competitive landscape report
- Amphothalide updates RSS · CI watch RSS
Frequently asked questions about Amphothalide
What is Amphothalide?
How does Amphothalide work?
What is the generic name of Amphothalide?
What development phase is Amphothalide in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing